Nicotine and/or nicotine agonists for the treatment of general anesthetic effects and side effects

• US 20040048900A1
• Filed: 06/17/2003
• Published: 03/11/2004
• Est. Priority Date: 06/17/2002
• Status: Abandoned Application

• Current Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Original Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Inventors: Flood, Pamela
• Application Number:
  US10/464,167
• Publication Number:
  US 20040048900A1
• Time in Patent Office: Days
• US Class Current: 514/343
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

This invention provides a method for reducing hyperalgesia following a pain-inducing procedure being performed on a subject which comprises administering to the subject an anesthetic which is an antagonist of the subject'"'"'s nicotinic acetylcholine receptor, in an amount effective to inhibit the subject'"'"'s perception of pain during the pain-inducing procedure; then performing the pain-inducing procedure on the subject; and administering to the subject a hyperalgesia-reducing amount of an agonist of the subject'"'"'s nicotinic acetylcholine receptor such that the subject'"'"'s hyperalgesia following the procedure is reduced. This invention also provides related methods and articles of manufacture.

Claims

1. A method for reducing hyperalgesia following a pain-inducing procedure being performed on a subject which comprises:

(a) administering to the subject an anesthetic which is an antagonist of the subject'"'"'s nicotinic acetylcholine receptor, in an amount effective to inhibit the subject'"'"'s perception of pain during the pain-inducing procedure;

(b) then performing the pain-inducing procedure on the subject; and

(c) administering to the subject a hyperalgesia-reducing amount of an agonist of the subject'"'"'s nicotinic acetylcholine receptor

such that the subject'"'"'s hyperalgesia following the procedure is reduced.

2. The method of claim 1, wherein steps (b) and (c) occur simultaneously.

3. The method of claim 1, wherein step (c) follows step (b).

4. The method of claim 1, wherein step (c) commences during step (b) and continues after step (b) is performed.

5. The method of claim 1, wherein the subject is a human.

6. The method of claim 1, wherein the subject is a male.

7. The method of claim 1, wherein the subject is a female.

8. The method of claim 7, wherein the female subject has a low level of circulating estrogen.

9. The method of claim 7, wherein the female subject is post-menopausal.

10. The method of claim 1, wherein the hyperalgesia consists of an enhanced sensitivity to pain.

11. The method of claim 1, wherein the pain-inducing procedure is a surgical procedure.

12. The method of claim 1, wherein the anesthetic is isoflurane, halothane, sevoflurane, desflurane, nitrous oxide, ketamine or a barbiturate.

13. The method of claim 1, wherein the nicotinic acetylcholine receptor agonist is administered intranasally.

14. The method of claim 1, wherein the nicotinic acetylcholine receptor agonist is administered transdermally.

15. The method of claim 1, wherein the nicotinic acetylcholine receptor agonist is nicotine.

16. The method of claim 15, wherein the nicotine dose is about 3 milligrams.

17. The method of claim 15, Wherein the nicotine is administered intranasally.

18. The method of claim 16, wherein the nicotine is administered intranasally.

19. The method of claim 1, wherein the nicotinic acetylcholine receptor agonist is administered via a single dose.

20. The method of claim 1, wherein the nicotinic acetylcholine receptor agonist is administered via a plurality of doses.

21. The method of claim 1, wherein the nicotinic acetylcholine receptor agonist is administered while the subject is conscious.

22. The method of claim 1, wherein the nicotinic acetylcholine receptor agonist is administered while the subject is unconscious.

23. The method of claim 1, further comprising administering to the subject during step (c) a pain-reducing amount of a narcotic agent.

24. The method of claim 23, wherein step (b) and step (c) are performed simultaneously.

25. The method of claim 23, wherein step (c) follows step (b).

26. The method of claim 23, wherein step (c) commences during step (b) and continues after step (b) is performed.

27. The method of claim 23, wherein the narcotic agent is morphine, meperidine, or fentanyl.

28. The method of claim 1, further comprising administering to the subject during step (c) a hyperalgesia-reducing amount of a steroid sex hormone.

29. The method of claim 28, wherein step (b) and step (c) are performed simultaneously.

30. The method of claim 28, wherein step (c) follows step (b).

31. The method of claim 28, wherein step (c) commences during step (b) and continues after step (b) is performed.

32. The method of claim 28, further comprising administering to the subject after step (c) a pain-reducing amount of a narcotic agent.

33. The method of claim 28, wherein the sex steroid hormone is a synthetic sex steroid hormone.

34. The method of claim 28, wherein the sex steroid hormone is estrogen.

35. The method of claim 28, wherein the sex steroid hormone is a synthetic estrogen.

36. The method of claim 28, wherein the sex steroid hormone is testosterone.

37. The method of claim 28, wherein the sex steroid hormone is a synthetic testosterone.

38. The method of claim 28, wherein the sex steroid hormone is progesterone.

39. The method of claim 28, wherein the sex steroid hormone is a synthetic progesterone.

40. The method of claim 28, wherein the nicotinic acetylcholine receptor agonist is nicotine.

41. The method of claim 28, wherein the nicotinic acetylcholine receptor agonist is administered intranasally.

42. The method of claim 28, wherein the nicotinic acetylcholine receptor agonist is administered transdermally.

43. The method of claim 28, wherein the nicotinic acetylcholine receptor agonist is administered via a single dose.

44. The method of claim 28, wherein the nicotinic acetylcholine receptor agonist is administered via a plurality of doses.

45. The method of claim 28, wherein the nicotinic acetylcholine receptor agonist is administered while the subject is conscious.

46. The method of claim 28, wherein the nicotinic acetylcholine receptor agonist is administered while the subject is unconscious.

47. An article of manufacture comprising a packaging material having therein a nicotinic acetylcholine receptor agonist and a label indicating a use of the agonist for reducing hyperalgesia in a subject having therein a hyperalgesia-inducing amount of an anesthetic that acts as a nicotinic acetylcholine receptor antagonist.

48. The article of claim 47, wherein the nicotinic acetylcholine receptor agonist is nicotine.

49. An article of manufacture comprising a packaging material having therein a nicotinic acetylcholine receptor agonist and a label indicating a use of the agonist for reducing enhanced pain sensitivity in a subject following surgery on the subject, which surgery employs an anesthetic that acts as a nicotinic acetylcholine receptor antagonist.

50. The article of manufacture of claim 49, wherein the nicotinic acetylcholine receptor agonist is nicotine.